Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors

To join this study, you generally need to have a confirmed diagnosis of certain types of advanced cancer that cannot be surgically removed or has spread. Your doctors will need to be able to measure your cancer, for example, on scans, and you'll need to provide a sample of your tumour tissue.

You must be 18 years or older and generally in good health, meaning you can carry out most of your daily activities without much trouble. Your blood tests for organ function and bone marrow should also be within acceptable limits.

There are also some reasons why you might not be able to join. For example, if you've already had either cabozantinib or certain other types of anti-cancer treatments that boost your immune system, or if you have certain brain metastases that aren't well-controlled. People who are pregnant or breastfeeding, or who are taking certain steroid medications or blood thinners, would also not be able to participate.

If you decide to take part in this study, you will receive either cabozantinib or atezolizumab, or a combination of both, depending on the stage of the study and your cancer type. Cabozantinib is usually given as tablets, and atezolizumab is given as an infusion into a vein, typically every three weeks. The study involves regular visits to the hospital for check-ups, blood tests, and scans to monitor your health and how your cancer is responding to the treatment. The total duration of your participation will depend on how you respond to the treatment and the specific part of the study you are in, but it will involve ongoing assessments and follow-up.